Since the start of the protocol, we have enrolled 34 survivors of childhood cancer. In collaboration with the Children's National Medical Center Center for Cancer and Blood Disorders of Northern Virginia in Fairfax, I have been providing endocrine care through the bi-monthly multidisciplinary late effects clinic for childhood cancer survivors. This also allows our fellows and rotating medical students an opportunity to learn how to best manage these patients. I participated in the 11th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer through St. Jude Children's research hospital, learning recent developments in research and forming collaborations. We continue to collect data on each patient through our secure electronic database regarding their cancer treatment record;all participants are invited to complete a child health questionnaire evaluating quality of life. Each patient undergoes an individualized screening and counseling program, with careful review of the following endocrine systems: growth, pituitary and hypothalamic function, thyroid function, ovary and testicular function, bone health, risk of obesity, insulin resistance, and metabolic syndrome. We are studying novel markers to assess ovarian function in women with a history of exposure to alkylating agents or radiation. In addition, out of this project, a number of collaborative studies have arisen related to patients with active malignancies and their endocrine abnormalities. In February 2011, in collaboration with the NHLBI, we extended the age of eligible cancer survivors and allowed participants who are survivors of hematopoietic stem cell transplants, regardless of whether they had a primary malignancy. In July of 2011, we added carotid MRI intima-media thickness measurements to screen for early evidence of athlerosclerotic plaque in HSCT survivors and survivors of pediatric malignancies.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Ramnitz, Mary Scott; Lodish, Maya B (2013) Racial disparities in pubertal development. Semin Reprod Med 31:333-9
Fox, Elizabeth; Widemann, Brigitte C; Chuk, Meredith K et al. (2013) Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 19:4239-48
Lodish, Maya B (2013) Clinical review: kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab 98:1333-42
Lodish, Maya (2013) Multiple endocrine neoplasia type 2. Front Horm Res 41:16-29
Briassoulis, George; Horvath, Anelia; Christoforou, Paola et al. (2012) Lack of mutations in the gene coding for the hGR (NR3C1) in a pediatric patient with ACTH-secreting pituitary adenoma, absence of stigmata of Cushing's syndrome and unusual histologic features. J Pediatr Endocrinol Metab 25:213-9
Lodish, Maya; Dunn, Somya Verma; Sinaii, Ninet et al. (2012) Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after surgical cure of Cushing's disease. J Clin Endocrinol Metab 97:1483-91
Rothenbuhler, Anya; Horvath, Anelia; Libé, Rossella et al. (2012) Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin Endocrinol (Oxf) 77:195-9
Lodish, Maya; Dagalakis, Urania; Chen, Clara C et al. (2012) (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents. J Clin Endocrinol Metab 97:E207-12
Lodish, Maya B; Dagalakis, Urania; Sinaii, Ninet et al. (2012) Bone mineral density in children and young adults with neurofibromatosis type 1. Endocr Relat Cancer 19:817-25
Lodish, Maya B; Mastroyannis, Spyridon A; Sinaii, Ninet et al. (2012) Known VDR polymorphisms are not associated with bone mineral density measures in pediatric Cushing disease. J Pediatr Endocrinol Metab 25:221-3

Showing the most recent 10 out of 11 publications